Cancer-free for 18 years: CAR-T therapy sets new milestone in neuroblastoma treatment

A groundbreaking study in Nature Medicine reveals that GD2 CAR-T cell therapy can lead to long-term remission in children with neuroblastoma, with one patient remaining cancer-free for over 18 years.

Sentara Health Taps RhythmX AI to Deploy Generative AI-Driven Co-Pilot for Clinicians

What You Should Know: RhythmX AI, a generative AI-native company driving revolutionary physician intelligence for whole-person care through cutting edge predictive and generative AI, announced

February 23, 2024

I’m moving forward and facing the uncertainty of aging

It takes a lot of courage to grow old. I’ve come to appreciate this after conversations with hundreds of older adults over the past eight

January 15, 2025

Astellas taps Poseida for second CAR-T deal focused on solid tumors

Astellas Pharma is signing Poseida Therapeutics to a second deal focused on developing off-the-shelf solid tumor cell therapies after the companies first teamed up in

May 2, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.